Heparin, an anticoagulant, has been shown to reduce neointimal proliferation and @entity256 following @entity1317 in experimental studies, but the clinical trials of heparin in @entity301 have been negative. The current study, therefore, examined the effect of heparin on basal or stimulated migration by serum and platelet-derived growth factor (PDGF)-BB in cultured @entity1 coronary artery smooth muscle cells (SMCs) by Boyden's chamber method. In addition, the reversibility of the heparin effect on @entity1 coronary artery @entity9976 migration was examined. Fetal calf serum (FCS) and PDGF-BB stimulated @entity9976 migration in a concentration-dependent manner. Heparin in moderate to high concentration (10 to 100 U/mL) exhibited concentration-related inhibition of FCS- and PDGF-BB-stimulated @entity9976 migration; however, a low concentration (1 U/mL) of heparin had no inhibitory effects. Heparin also had weak inhibitory effects on nonstimulated @entity9976 migration. The SMCs that were exposed to a high concentration (100 U/mL) of heparin for 6 hours were capable of migrating after a short lag period of removal of heparin from the culture medium. These SMCs also showed recovery of responses to FCS and PDGF-BB by migrating significantly greater than the nonstimulated level. Furthermore, heparin-containing medium did not contain detached cells. These results indicate that heparin inhibits @entity1 coronary artery @entity9976 migration, especially when stimulated by FCS or PDGF-BB, and that this inhibitory effect of heparin is reversible and not simply a function of killing cells.

Heparin inhibits XXXX coronary artery smooth muscle cell migration.

@entity1 :: ('9606', 'Species') :: ['human'] @entity9976 :: ('MESH:C564589', 'Disease') :: ['SMC'] @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary balloon angioplasty'] @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis'] @entity1317 :: ('MESH:D057772', 'Disease') :: ['vascular injury']
@entity1 :: (9606,Species) :: ['human']
